• Publications
  • Influence
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
TLDR
When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
TLDR
New consensus criteria for eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone are defined, with increasing emphasis on time-to-event end points as decision aids in proceeding from phase II to phase III trials.
Measuring health-related quality of life.
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.
TLDR
A high NLR is associated with an adverse OS in many solid tumors, and its addition to established prognostic scores for clinical decision making warrants further investigation.
Drug penetration in solid tumours
TLDR
The evidence that indicates that the distribution of many anticancer drugs in tumours is incomplete is summarized, and strategies that might be used either to improve drug penetration through tumour tissue or to select compounds based on their abilities to penetrate tissue are suggested, thereby increasing the therapeutic index.
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
TLDR
Chemotherapy with mitoxantrone and prednisone provides palliation for some patients with symptomatic hormone-resistant prostate cancer and most responding patients had an improvement in quality-of-life scales and a decrease in serum prostate-specific antigen (PSA) level.
Drug resistance and the solid tumor microenvironment.
TLDR
How the tumor microenvironment may be involved in the resistance of solid tumors to chemotherapy and potential strategies to improve the effectiveness of drug treatment by modifying factors relating to the tumormicroenvironment are described.
Acid pH in tumors and its potential for therapeutic exploitation.
TLDR
Measurement of pH in tissue has shown that the microenvironment in tumors is generally more acidic than in normal tissues, and acid conditions in tumors might allow the development of new and relatively specific types of therapy which are directed against mechanisms which regulate pHi under acid conditions.
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
TLDR
It is confirmed that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP, and consistent results are observed across subgroups of patients.
Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study.
TLDR
Fatigue, menopausal symptoms, and cognitive dysfunction are important adverse effects of chemotherapy that improve in most patients and Hormonal treatment has minimal impact on them.
...
...